Eintrag weiter verarbeiten
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 28, 2010, 14, S. 2348-2355 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. |
|---|---|
| author |
Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. |
| spellingShingle |
Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. Journal of Clinical Oncology IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Cancer Research Oncology |
| author_sort |
marcucci, guido |
| spelling |
Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2009.27.3730 <jats:sec><jats:title>Purpose</jats:title><jats:p> To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 IDH2 mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (NPM1-mutated/FLT3-internal tandem duplication–negative) IDH1-mutated patients had shorter disease-free survival than molecular low-risk IDH1/IDH2-wild-type (wt) patients (P = .046). R172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 IDH2 mutations. The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> IDH1 and IDH2 mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms. </jats:p></jats:sec> <i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2009.27.3730 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNy4zNzMw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNy4zNzMw |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2010 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
marcucci2010idh1andidh2genemutationsidentifynovelmolecularsubsetswithindenovocytogeneticallynormalacutemyeloidleukemiaacancerandleukemiagroupbstudy |
| publishDateSort |
2010 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_unstemmed |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_full |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_fullStr |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_full_unstemmed |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_short |
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_sort |
<i>idh1</i> and <i>idh2</i> gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group b study |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2009.27.3730 |
| publishDate |
2010 |
| physical |
2348-2355 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 IDH2 mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (NPM1-mutated/FLT3-internal tandem duplication–negative) IDH1-mutated patients had shorter disease-free survival than molecular low-risk IDH1/IDH2-wild-type (wt) patients (P = .046). R172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 IDH2 mutations. The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> IDH1 and IDH2 mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms. </jats:p></jats:sec> |
| container_issue |
14 |
| container_start_page |
2348 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
28 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347756317114371 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:00:20.793Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=IDH1+and+IDH2+Gene+Mutations+Identify+Novel+Molecular+Subsets+Within+De+Novo+Cytogenetically+Normal+Acute+Myeloid+Leukemia%3A+A+Cancer+and+Leukemia+Group+B+Study&rft.date=2010-05-10&genre=article&issn=1527-7755&volume=28&issue=14&spage=2348&epage=2355&pages=2348-2355&jtitle=Journal+of+Clinical+Oncology&atitle=%3Ci%3EIDH1%3C%2Fi%3E+and+%3Ci%3EIDH2%3C%2Fi%3E+Gene+Mutations+Identify+Novel+Molecular+Subsets+Within+De+Novo+Cytogenetically+Normal+Acute+Myeloid+Leukemia%3A+A+Cancer+and+Leukemia+Group+B+Study&aulast=Bloomfield&aufirst=Clara+D.&rft_id=info%3Adoi%2F10.1200%2Fjco.2009.27.3730&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347756317114371 |
| author | Marcucci, Guido, Maharry, Kati, Wu, Yue-Zhong, Radmacher, Michael D., Mrózek, Krzysztof, Margeson, Dean, Holland, Kelsi B., Whitman, Susan P., Becker, Heiko, Schwind, Sebastian, Metzeler, Klaus H., Powell, Bayard L., Carter, Thomas H., Kolitz, Jonathan E., Wetzler, Meir, Carroll, Andrew J., Baer, Maria R., Caligiuri, Michael A., Larson, Richard A., Bloomfield, Clara D. |
| author_facet | Marcucci, Guido, Maharry, Kati, Wu, Yue-Zhong, Radmacher, Michael D., Mrózek, Krzysztof, Margeson, Dean, Holland, Kelsi B., Whitman, Susan P., Becker, Heiko, Schwind, Sebastian, Metzeler, Klaus H., Powell, Bayard L., Carter, Thomas H., Kolitz, Jonathan E., Wetzler, Meir, Carroll, Andrew J., Baer, Maria R., Caligiuri, Michael A., Larson, Richard A., Bloomfield, Clara D., Marcucci, Guido, Maharry, Kati, Wu, Yue-Zhong, Radmacher, Michael D., Mrózek, Krzysztof, Margeson, Dean, Holland, Kelsi B., Whitman, Susan P., Becker, Heiko, Schwind, Sebastian, Metzeler, Klaus H., Powell, Bayard L., Carter, Thomas H., Kolitz, Jonathan E., Wetzler, Meir, Carroll, Andrew J., Baer, Maria R., Caligiuri, Michael A., Larson, Richard A., Bloomfield, Clara D. |
| author_sort | marcucci, guido |
| container_issue | 14 |
| container_start_page | 2348 |
| container_title | Journal of Clinical Oncology |
| container_volume | 28 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 IDH2 mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (NPM1-mutated/FLT3-internal tandem duplication–negative) IDH1-mutated patients had shorter disease-free survival than molecular low-risk IDH1/IDH2-wild-type (wt) patients (P = .046). R172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 IDH2 mutations. The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> IDH1 and IDH2 mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2009.27.3730 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwOS4yNy4zNzMw |
| imprint | American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2010 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T18:00:20.793Z |
| match_str | marcucci2010idh1andidh2genemutationsidentifynovelmolecularsubsetswithindenovocytogeneticallynormalacutemyeloidleukemiaacancerandleukemiagroupbstudy |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2348-2355 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Marcucci, Guido Maharry, Kati Wu, Yue-Zhong Radmacher, Michael D. Mrózek, Krzysztof Margeson, Dean Holland, Kelsi B. Whitman, Susan P. Becker, Heiko Schwind, Sebastian Metzeler, Klaus H. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Carroll, Andrew J. Baer, Maria R. Caligiuri, Michael A. Larson, Richard A. Bloomfield, Clara D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2009.27.3730 <jats:sec><jats:title>Purpose</jats:title><jats:p> To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 and IDH2 mutations by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, and MLL mutational analyses and gene- and microRNA-expression profiling were performed centrally. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> IDH mutations were found in 33% of the patients. IDH1 mutations were detected in 49 patients (14%; 47 with R132). IDH2 mutations, previously unreported in AML, were detected in 69 patients (19%; 13 with R172 and 56 with R140). R172 IDH2 mutations were mutually exclusive with all other prognostic mutations analyzed. Younger age (< 60 years), molecular low-risk (NPM1-mutated/FLT3-internal tandem duplication–negative) IDH1-mutated patients had shorter disease-free survival than molecular low-risk IDH1/IDH2-wild-type (wt) patients (P = .046). R172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007). Distinctive microarray gene- and microRNA-expression profiles accurately predicted R172 IDH2 mutations. The highest expressed gene and microRNAs in R172 IDH2-mutated patients compared with the IDH1/IDH2wt patients were APP (previously associated with complex karyotype AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> IDH1 and IDH2 mutations are recurrent in CN-AML and have an unfavorable impact on outcome. The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms. </jats:p></jats:sec> <i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Journal of Clinical Oncology |
| spellingShingle | Marcucci, Guido, Maharry, Kati, Wu, Yue-Zhong, Radmacher, Michael D., Mrózek, Krzysztof, Margeson, Dean, Holland, Kelsi B., Whitman, Susan P., Becker, Heiko, Schwind, Sebastian, Metzeler, Klaus H., Powell, Bayard L., Carter, Thomas H., Kolitz, Jonathan E., Wetzler, Meir, Carroll, Andrew J., Baer, Maria R., Caligiuri, Michael A., Larson, Richard A., Bloomfield, Clara D., Journal of Clinical Oncology, IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study, Cancer Research, Oncology |
| title | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_full | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_fullStr | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_full_unstemmed | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_short | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| title_sort | <i>idh1</i> and <i>idh2</i> gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group b study |
| title_unstemmed | IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2009.27.3730 |